FDA

FDA

ORG Government / Drug and Device Regulation Momentum 29.7ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. CRITICALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

FDA (6,900 employees, $6.5B budget) regulates drugs, biologics, devices, and food products representing roughly 20% of US consumer spending. Agency accelerated 53 novel drug approvals in 2025 and launched drug repurposing initiative; Commissioner Makary departed May 2026 following internal conflict over regulatory direction.

FDA Commissioner Marty Makary resigned in May 2026 amid organizational turmoil; agency leadership transition underway with food safety official Diamantas stepping into interim role.

-0.06

PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.

29.7

MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.

ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.

ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.

FDA is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).

PSI Intelligence

30-Day Trend

Signal Decomposition

Attention Cascade

-1.583

Narrative Drift

0.000

Spectral Shift

624.046

Sentiment-Momentum Divergence

0.000

Source Concentration

0.848

Signal

FDA is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).

Driver

Ranked #10 of 10 in Government — in line with sector peers. PSI stable vs yesterday (-1.00). Confidence: 63% (entity has limited history, score is shrunk toward sector prior).

Action

Baseline conditions. Continue standard monitoring cadence.

Peer Comparison

10 of 10

Sector Rank

+0.00

Peer Z-Score

Sector Percentile

Network Analysis

35 Degree Centrality

Ego Network (top connections)

Centrality History

Entity	Weight	Status
United States	43	STABLE
White House	36	STABLE
HHS	30	STABLE
WASHINGTON	24	STABLE
Dr.	22	NEW
AstraZeneca	18	NEW
Novo Nordisk	16	NEW
RFK Jr.	14	NEW
Pfizer	11	STABLE
President	9	STABLE
China	8	STABLE
Supreme Court	8	STABLE
Eli Lilly	8	NEW
AP	8	STABLE
CMS	8	STABLE
Sanofi	7	NEW
Senate	7	STABLE
Kennedy	7	NEW
Donald Trump	6	STABLE
Reuters	6	STABLE
Rocket	6	NEW
Iran	5	STABLE
GOP	5	STABLE
Louisiana	5	NEW
Europe	4	STABLE
CEO	4	STABLE
Americans	4	STABLE
Congress	4	STABLE
European Union	4	STABLE
Washington, D.C.	3	NEW

Article Coverage (0)

Date	Lane	Title
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

FDA+ Note this entity

Request Access